Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STM-21
- Development stage
- Preclinical
- Lead developer
- Secretome Therapeutics
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
STM-21 is a preclinical-stage cell therapy candidate developed by Secretome Therapeutics. It is derived from neonatal cardiac progenitor cells (nCPCs) and focuses on utilizing the cellular secretome—the collection of proteins, growth factors, and exosomes secreted by the cells—to treat inflammatory and degenerative conditions. The asset is currently being evaluated for the treatment of neurological and skin conditions. Secretome Therapeutics has partnered with RoosterBio to develop a scalable, 50L cGMP-compatible bioreactor-based manufacturing process to support the transition from preclinical development to future clinical trials.
Beyond the preview
Go deeper on STM-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STM-21.